Last reviewed · How we verify
LMN-201 Anti-toxin B VHH-1, VHH-2, VHH-3
LMN-201 Anti-toxin B VHH-1, VHH-2, VHH-3 is a Biologic drug developed by Lumen Bioscience, Inc.. It is currently in Phase 1 development.
At a glance
| Generic name | LMN-201 Anti-toxin B VHH-1, VHH-2, VHH-3 |
|---|---|
| Sponsor | Lumen Bioscience, Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LMN-201 Anti-toxin B VHH-1, VHH-2, VHH-3 CI brief — competitive landscape report
- LMN-201 Anti-toxin B VHH-1, VHH-2, VHH-3 updates RSS · CI watch RSS
- Lumen Bioscience, Inc. portfolio CI
Frequently asked questions about LMN-201 Anti-toxin B VHH-1, VHH-2, VHH-3
What is LMN-201 Anti-toxin B VHH-1, VHH-2, VHH-3?
LMN-201 Anti-toxin B VHH-1, VHH-2, VHH-3 is a Biologic drug developed by Lumen Bioscience, Inc..
Who makes LMN-201 Anti-toxin B VHH-1, VHH-2, VHH-3?
LMN-201 Anti-toxin B VHH-1, VHH-2, VHH-3 is developed by Lumen Bioscience, Inc. (see full Lumen Bioscience, Inc. pipeline at /company/lumen-bioscience-inc).
What development phase is LMN-201 Anti-toxin B VHH-1, VHH-2, VHH-3 in?
LMN-201 Anti-toxin B VHH-1, VHH-2, VHH-3 is in Phase 1.